Dr. Dreicer on Combination Therapies in Prostate Cancer

Robert Dreicer, MD
Published: Wednesday, Mar 20, 2013

Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute and professor of Medicine at the Cleveland Clinic in Ohio, describes potential combination therapies currently being considered as treatments for men with prostate cancer.

Currently, Dreicer notes, a phase I/II trial is investigating the combination of the androgen receptor (AR) antagonist enzalutamide and the lyase inhibitor abiraterone acetate. This combination is supported by preclinical evidence that suggest synergy between these agents.

Dreicer notes that researchers are interested in the combination of AR antagonists with novel agents, such as sipuleucel-T (Provenge) and radium-223. In general, the agents approved to treat prostate cancer have varying mechanisms of action and favorable toxicity profiles, which provides an abundance of potential for novel combinations.
 
SELECTED
LANGUAGE
Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute and professor of Medicine at the Cleveland Clinic in Ohio, describes potential combination therapies currently being considered as treatments for men with prostate cancer.

Currently, Dreicer notes, a phase I/II trial is investigating the combination of the androgen receptor (AR) antagonist enzalutamide and the lyase inhibitor abiraterone acetate. This combination is supported by preclinical evidence that suggest synergy between these agents.

Dreicer notes that researchers are interested in the combination of AR antagonists with novel agents, such as sipuleucel-T (Provenge) and radium-223. In general, the agents approved to treat prostate cancer have varying mechanisms of action and favorable toxicity profiles, which provides an abundance of potential for novel combinations.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x